Cryoport (NASDAQ:CYRX) Upgraded at UBS Group

UBS Group upgraded shares of Cryoport (NASDAQ:CYRX) from a neutral rating to a buy rating in a research report released on Monday morning, Marketbeat.com reports. The brokerage currently has $10.00 target price on the stock.

A number of other brokerages have also issued reports on CYRX. Guggenheim initiated coverage on shares of Cryoport in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 target price on the stock. Needham & Company LLC restated a “buy” rating and issued a $11.00 price objective on shares of Cryoport in a research report on Wednesday, March 5th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.67.

Cryoport Stock Down 0.3 %

Shares of CYRX opened at $6.22 on Monday. The company has a market capitalization of $310.44 million, a P/E ratio of -1.84 and a beta of 1.67. Cryoport has a one year low of $4.58 and a one year high of $20.11. The business’s 50 day simple moving average is $6.73 and its 200-day simple moving average is $7.34. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32.

Cryoport (NASDAQ:CYRX) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The business had revenue of $59.53 million during the quarter, compared to analyst estimates of $58.71 million. During the same period in the prior year, the firm posted ($0.29) EPS. As a group, sell-side analysts predict that Cryoport will post -0.99 EPS for the current fiscal year.

Insider Transactions at Cryoport

In other news, CEO Jerrell Shelton sold 4,620 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $6.29, for a total value of $29,059.80. Following the transaction, the chief executive officer now directly owns 765,399 shares in the company, valued at $4,814,359.71. This trade represents a 0.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 19,830 shares of company stock worth $118,353 in the last quarter. 10.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Cryoport

Several hedge funds have recently added to or reduced their stakes in the stock. Franklin Resources Inc. grew its position in shares of Cryoport by 0.4% during the 4th quarter. Franklin Resources Inc. now owns 387,131 shares of the company’s stock worth $3,012,000 after buying an additional 1,512 shares during the period. Rhumbline Advisers lifted its holdings in shares of Cryoport by 2.9% during the 4th quarter. Rhumbline Advisers now owns 63,284 shares of the company’s stock valued at $492,000 after purchasing an additional 1,764 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. grew its position in shares of Cryoport by 148.7% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock valued at $28,000 after purchasing an additional 2,120 shares during the period. Nebula Research & Development LLC increased its stake in Cryoport by 21.6% during the 4th quarter. Nebula Research & Development LLC now owns 12,442 shares of the company’s stock worth $97,000 after purchasing an additional 2,207 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Cryoport by 0.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 387,714 shares of the company’s stock worth $3,144,000 after buying an additional 2,226 shares during the period. Institutional investors and hedge funds own 92.90% of the company’s stock.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.